ProfileGDS5678 / 1416207_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 82% 83% 86% 83% 82% 84% 83% 84% 82% 83% 81% 82% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8762582
GSM967853U87-EV human glioblastoma xenograft - Control 26.0141882
GSM967854U87-EV human glioblastoma xenograft - Control 36.0116983
GSM967855U87-EV human glioblastoma xenograft - Control 46.7387786
GSM967856U87-EV human glioblastoma xenograft - Control 56.1063383
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7668782
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0624884
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1124583
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2047684
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0057482
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0397983
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8887181
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.9436482
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.9062182